5/29/2013

A study presented at the Heart Failure Congress found type 2 diabetes patients with heart failure who took vildagliptin attained lower HbA1C levels at 16 weeks compared with those in the placebo group. However, researchers noted higher rates of cardiovascular and all-cause mortality in vildagliptin-treated patients.

Related Summaries